Aileron Therapeutics, Inc.
ALRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $54 | $0 | $45 | $46 |
| - Cash | $4 | $6 | $7 | $13 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $50 | -$6 | $37 | $33 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$6 | -$7 | -$6 | -$41 |
| % Margin | – | – | – | -32,527.8% |
| Net Income | -$6 | -$7 | -$6 | -$41 |
| % Margin | – | – | – | -32,524.6% |
| EPS Diluted | -0.21 | -0.28 | -0.25 | -2.07 |
| % Growth | 25% | -12% | 87.9% | – |
| Operating Cash Flow | -$4 | -$6 | -$6 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$6 | -$6 | -$5 |